In a significant development signaling a strong and continued endorsement of Allay Therapeutics’ innovative strategy and potential for growth, a consortium of investors, led by Lightstone Ventures and Temasek’s ClavystBio, has jointly spearheaded a US$57.5 million Series D funding round for the biotech company. This cash infusion places Allay Therapeutics on a robust financial footing […]